Endotronix and Millar enter partnership granting Millar exclusive rights to Endotronix MEMS sensor technology in the neurosurgical care market.
Millar, Inc., a medical device and OEM solutions company, and Endotronix, Inc., a digital health medtech company providing solutions for patients who suffer from advanced heart failure, are pleased to announce an agreement that grants Millar exclusive rights to the Endotronix wireless MEMS sensor technology for sales and development in the neurosurgical care market. The technology will be developed for at-home monitoring of intracranial pressure (ICP) for patients suffering from hydrocephalus to improve quality of life and reduce treatment costs.
“The implantable Endotronix sensor technology is an excellent complement to our existing catheter-based MEMS pressure sensor offerings. We have a 25-year history in sensor-enabled catheters for monitoring ICP following a traumatic brain injury,” stated Simon Malpas, CSO, Millar. “More recently we have focused on implantable MEMS platforms to expand the utility for neurosurgeons and medical researchers. We believe the Endotronix technology can provide reliable, real-time ICP measurements that will positively impact patient outcomes.”
Millar is a leading manufacturer of high-fidelity pressure sensors for the medical device, cardiovascular and basic science markets. The company’s MEMS pressure sensors have been recognized as the gold standard for pressure measurement and are utilized daily in cardiac cath labs, pharmaceutical discovery, and research laboratories around the world. Millar sensor-enabled catheters have played a crucial role in advancing scientific understanding in the life sciences while also providing the most accurate pressure measurements for the validation of new life-saving drug compounds and innovative medical devices.
“We believe the core sensor technology and patient management platform used in the Endotronix Cordella™ Heart Failure System has applications beyond the cardiovascular space to provide clinical-grade vital sign monitoring with improved patient-physician communication,” commented Harry Rowland, CEO, Endotronix. “We are thrilled to partner with Millar which has an impressive history in the neurosurgical care market.”
Endotronix is an iBIO member and participates in the PROPEL Center.